DOCSLIB.ORG

Nmslabs 2018 Setup Days / TAT Update Effective: October 15, 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nmslabs 2018 Setup Days / TAT Update Effective: October 15, 2018 NMSLabs 2018 Setup Days / TAT Update Effective: October 15, 2018 Test Test Name Method Setup Days TAT 0011U 2-Butoxyethanol Metabolite (2-Butoxyacetic Acid - Total), GC/MS Monday-Sunday 7 days Urine 0012B Acebutolol, Blood LC-MS/MS Monday-Sunday 7 days 0012SP Acebutolol, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0017B Acepromazine, Blood GC Monday-Sunday 7 days 0017SP Acepromazine, Serum/Plasma GC Monday-Sunday 7 days 0017U Acepromazine, Urine GC Monday-Sunday 7 days 0021B Acetaldehyde, Blood Headspace GC Monday-Sunday 4 days 0021SP Acetaldehyde, Serum/Plasma Headspace GC Monday-Sunday 4 days 0021U Acetaldehyde, Urine Headspace GC Monday-Sunday 4 days 0030B Acetaminophen, Blood HPLC Monday-Sunday 4 days 0030FL Acetaminophen, Fluid HPLC Monday-Sunday 4 days 0030SP Acetaminophen, Serum/Plasma HPLC Monday-Sunday 4 days 0030TI Acetaminophen, Tissue HPLC Monday-Sunday 4 days 0030U Acetaminophen, Urine HPLC Monday-Sunday 4 days 0032B Acetaminophen Screen, Blood ELISA Monday-Sunday 7 days 0032SP Acetaminophen Screen, Serum/Plasma ELISA Monday-Sunday 7 days 0032U Acetaminophen Screen, Urine ELISA Monday-Sunday 7 days 0050B Acetazolamide, Blood HPLC Monday-Sunday 4 days 0050SP Acetazolamide, Serum/Plasma HPLC Monday-Sunday 4 days 0050U Acetazolamide, Urine HPLC Monday-Sunday 4 days 0060SP Acetoacetate, Serum/Plasma GC Monday-Sunday 7 days 0060U Acetoacetate, Urine GC Monday-Sunday 7 days 0080B Acetone, Blood Headspace GC Monday-Sunday 4 days 0080FL Acetone, Fluid Headspace GC Monday-Sunday 4 days 0080SP Acetone, Serum/Plasma Headspace GC Monday-Sunday 4 days 0080U Acetone, Urine Headspace GC Monday-Sunday 4 days 0088B Acetonitrile Exposure Profile, Blood Headspace GC Monday-Sunday 4 days 0088B Acetonitrile Exposure Profile, Blood LC-MS/MS Monday-Sunday 7 days 0088U Acetonitrile Exposure Profile, Urine GC Monday-Sunday 7 days 0088U Acetonitrile Exposure Profile, Urine IC Monday-Sunday 7 days 0088U Acetonitrile Exposure Profile, Urine Colorimetry Monday-Sunday 1 day 0094U 2,5-Hexanedione, Urine GC Monday-Sunday 7 days 0148B Acrylonitrile Exposure Profile, Blood Headspace GC Monday-Sunday 4 days 0148B Acrylonitrile Exposure Profile, Blood LC-MS/MS Monday-Sunday 7 days 0148U Acrylonitrile Exposure Profile, Urine GC Monday-Sunday 7 days 0148U Acrylonitrile Exposure Profile, Urine IC Monday-Sunday 7 days 0148U Acrylonitrile Exposure Profile, Urine Colorimetry Monday-Sunday 1 day Page 1 of 143 NMSLabs 2018 Setup Days / TAT Update Effective: October 15, 2018 Test Test Name Method Setup Days TAT 0158SP Acyclovir, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0158U Acyclovir, Urine LC-MS/MS Monday-Sunday 7 days 0165B Albuterol, Blood LC-MS/MS Monday-Sunday 7 days 0165FL Albuterol, Fluid LC-MS/MS Monday-Sunday 7 days 0165SP Albuterol, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0165TI Albuterol, Tissue LC-MS/MS Monday-Sunday 7 days 0166B Acyclovir, Blood LC-MS/MS Monday-Sunday 7 days 0170B Alcohol Panel, Blood Headspace GC Monday-Sunday 4 days 0170FL Alcohol Panel, Fluid Headspace GC Monday-Sunday 4 days 0170SP Alcohol Panel, Serum/Plasma Headspace GC Monday-Sunday 4 days 0170TI Alcohol Panel, Tissue Headspace GC Monday-Sunday 4 days 0170U Alcohol Panel, Urine Headspace GC Monday-Sunday 4 days 0171B Alcohol Screen, Blood Headspace GC Monday-Sunday 4 days 0171FL Alcohol Screen, Fluid Headspace GC Monday-Sunday 4 days 0171SP Alcohol Screen, Serum/Plasma Headspace GC Monday-Sunday 4 days 0171TI Alcohol Screen, Tissue Headspace GC Monday-Sunday 4 days 0171U Alcohol Screen, Urine Headspace GC Monday-Sunday 4 days 0175B Alcohol, Blood (Forensic) Headspace GC Monday-Sunday 3 days 0175B Alcohol, Blood (Forensic) Headspace GC Monday-Sunday 3 days 0175SP Alcohol, Serum/Plasma (Forensic) Headspace GC Monday-Sunday 3 days 0175SP Alcohol, Serum/Plasma (Forensic) Headspace GC Monday-Sunday 3 days 0175U Alcohol, Urine (Forensic) Headspace GC Monday-Sunday 3 days 0175U Alcohol, Urine (Forensic) Headspace GC Monday-Sunday 3 days 0177LI Alcohol In Suspected Alcoholic Beverages Headspace GC Monday-Sunday 7 days 0177LI Alcohol In Suspected Alcoholic Beverages Headspace GC Monday-Sunday 7 days 0190B Aldrin/Dieldrin, Blood GC Monday-Sunday 7 days 0190SP Aldrin/Dieldrin, Serum/Plasma GC Monday-Sunday 7 days 0200B Alfentanil, Blood LC-MS/MS Monday-Sunday 3 days 0200SP Alfentanil, Serum/Plasma LC-MS/MS Monday-Sunday 3 days 0205B Acetyl Fentanyl, Blood LC-MS/MS Monday-Sunday 3 days 0205SP Acetyl Fentanyl, Serum/Plasma LC-MS/MS Monday-Sunday 3 days 0205U Acetyl Fentanyl and Metabolite, Urine LC-MS/MS Monday-Sunday 4 days 0213B Allopurinol and Metabolite, Blood HPLC Monday-Sunday 7 days 0213SP Allopurinol and Metabolite, Serum/Plasma HPLC Monday-Sunday 7 days 0260B Alprazolam, Blood LC-MS/MS Monday-Sunday 3 days 0260FL Alprazolam, Fluid LC-MS/MS Monday-Sunday 3 days 0260SP Alprazolam, Serum/Plasma LC-MS/MS Monday-Sunday 3 days 0260TI Alprazolam, Tissue LC-MS/MS Monday-Sunday 3 days Page 2 of 143 NMSLabs 2018 Setup Days / TAT Update Effective: October 15, 2018 Test Test Name Method Setup Days TAT 0264B Aluminum, Blood ICP/MS Monday-Sunday 7 days 0264FL Aluminum, Fluid ICP/MS Monday-Sunday 7 days 0264H Aluminum, Hair ICP/MS Monday-Sunday 8 days 0264LI Aluminum, Liquid ICP/MS Monday-Sunday 7 days 0264N Aluminum, Nails ICP/MS Monday-Sunday 8 days 0264R Aluminum, RBCs ICP/MS Monday-Sunday 7 days 0264SP Aluminum, Serum/Plasma ICP/MS Monday-Sunday 7 days 0264TI Aluminum, Tissue ICP/MS Monday-Sunday 7 days 0264U Aluminum, Urine ICP/MS Monday-Sunday 7 days 0264UH Aluminum, 24 Hour Urine ICP/MS Monday-Sunday 7 days 0265B Amantadine, Blood GC Monday-Sunday 4 days 0265FL Amantadine, Fluid GC Monday-Sunday 4 days 0265SP Amantadine, Serum/Plasma GC Monday-Sunday 4 days 0265U Amantadine, Urine GC Monday-Sunday 4 days 0269SP Aminocaproic Acid, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0273U Aniline Exposure (Aminophenol, para-), Urine SP Monday-Sunday 7 days 0307B Amiodarone and Metabolite, Blood LC-MS/MS Monday-Sunday 7 days 0307SP Amiodarone and Metabolite, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0310B Amitriptyline and Metabolite, Blood GC Monday-Sunday 3 days 0310SP Amitriptyline and Metabolite, Serum/Plasma GC Monday-Sunday 3 days 0310TI Amitriptyline and Metabolite, Tissue GC Monday-Sunday 3 days 0310U Amitriptyline and Metabolite, Urine GC Monday-Sunday 3 days 0315B Amlodipine, Blood LC-MS/MS Monday-Sunday 7 days 0315SP Amlodipine, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0320SP Amobarbital, Serum/Plasma GC/MS Monday-Sunday 4 days 0320U Amobarbital, Urine GC/MS Monday-Sunday 4 days 0325B Amoxapine and Metabolite, Blood HPLC Monday-Sunday 7 days 0325SP Amoxapine and Metabolite, Serum/Plasma HPLC Monday-Sunday 7 days 0325U Amoxapine and Metabolite, Urine HPLC Monday-Sunday 7 days 0329B Amphetamines (D/L Differentiation), Blood LC-MS/MS Monday-Sunday 7 days 0329FL Amphetamines (D/L Differentiation), Fluid LC-MS/MS Monday-Sunday 7 days 0329SP Amphetamines (D/L Differentiation), Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0329U Amphetamines (D/L Differentiation), Urine LC-MS/MS Monday-Sunday 7 days 0337B Amphetamines Screen, Blood ELISA Monday-Sunday 3 days 0337FL Amphetamines Screen, Fluid ELISA Monday-Sunday 7 days 0337SP Amphetamines Screen, Serum/Plasma ELISA Monday-Sunday 3 days 0337U Amphetamines Screen, Urine EIA Monday-Sunday 4 days Page 3 of 143 NMSLabs 2018 Setup Days / TAT Update Effective: October 15, 2018 Test Test Name Method Setup Days TAT 0390U Aniline Exposure, Urine Colorimetry Monday-Sunday 1 day 0390U Aniline Exposure, Urine SP Monday-Sunday 7 days 0410B Antimony, Blood ICP/MS Monday-Sunday 4 days 0410H Antimony, Hair ICP/MS Monday-Sunday 8 days 0410LI Antimony, Liquid ICP/MS Monday-Sunday 7 days 0410N Antimony, Nails ICP/MS Monday-Sunday 8 days 0410R Antimony, RBCs ICP/MS Monday-Sunday 7 days 0410SP Antimony, Serum/Plasma ICP/MS Monday-Sunday 4 days 0410U Antimony, Urine ICP/MS Monday-Sunday 7 days 0410U Antimony, Urine Colorimetry Monday-Sunday 1 day 0420B Betahydroxybutyric Acid, Blood GC/MS Monday-Sunday 7 days 0420FL Betahydroxybutyric Acid, Fluid GC/MS Monday-Sunday 7 days 0425B Antipyrine, Blood LC-MS/MS Monday-Sunday 7 days 0425SP Antipyrine, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0430U Aromatic Solvents Metabolites Panel 2, Urine LC-MS/MS Monday-Sunday 7 days 0430U Aromatic Solvents Metabolites Panel 2, Urine GC Monday-Sunday 4 days 0430U Aromatic Solvents Metabolites Panel 2, Urine Colorimetry Monday-Sunday 1 day 0448SP Apixaban, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0450SP Aprobarbital, Serum/Plasma GC Monday-Sunday 7 days 0450U Aprobarbital, Urine GC Monday-Sunday 7 days 0451B Aripiprazole, Blood LC-MS/MS Monday-Sunday 7 days 0451SP Aripiprazole, Serum/Plasma LC-MS/MS Monday-Sunday 7 days 0460B Arsenic, Blood ICP/MS Monday-Sunday 4 days 0460FL Arsenic, Fluid ICP/MS Monday-Sunday 7 days 0460H Arsenic, Hair ICP/MS Monday-Sunday 8 days 0460N Arsenic, Nails ICP/MS Monday-Sunday 8 days 0460R Arsenic, RBCs ICP/MS Monday-Sunday 7 days 0460SL Arsenic, Solid ICP/MS Monday-Sunday 8 days 0460SP Arsenic, Serum/Plasma ICP/MS Monday-Sunday 4 days 0460TI Arsenic, Tissue ICP/MS Monday-Sunday 7 days 0460U Arsenic, Urine ICP/MS Monday-Sunday 7 days 0460U Arsenic, Urine Colorimetry Monday-Sunday 1 day 0460UH Arsenic, 24 Hour Urine ICP/MS Monday-Sunday 7 days 0468U Arsenic, Total Inorganic, Urine ICP/MS Monday-Sunday 7 days 0468U Arsenic, Total Inorganic, Urine Colorimetry Monday-Sunday 1 day 0468UH Arsenic, Total Inorganic, 24 Hour Urine ICP/MS Monday-Sunday 7 days 0470UH Total, Inorganic Arsenic, 24 Hour Urine (+Creatinine) ICP/MS Monday-Sunday 7 days Page
Load more

Recommended publications
  • Therapeutic Class Brand Name P a Status Generic
    P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE
    [Show full text]
  • Carbamate Pesticides Aldicarb Aldicarb Sulfoxide Aldicarb Sulfone
    Connecticut General Statutes Sec 19a-29a requires the Commissioner of Public Health to annually publish a list setting forth all analytes and matrices for which certification for testing is required. Connecticut ELCP Drinking Water Analytes Revised 05/31/2018 Microbiology Total Coliforms Fecal Coliforms/ E. Coli Carbamate Pesticides Legionella Aldicarb Cryptosporidium Aldicarb Sulfoxide Giardia Aldicarb Sulfone Carbaryl Physicals Carbofuran Turbidity 3-Hydroxycarbofuran pH Methomyl Conductivity Oxamyl (Vydate) Minerals Chlorinated Herbicides Alkalinity, as CaCO3 2,4-D Bromide Dalapon Chloride Dicamba Chlorine, free residual Dinoseb Chlorine, total residual Endothall Fluoride Picloram Hardness, Calcium as Pentachlorophenol CaCO3 Hardness, Total as CaCO3 Silica Chlorinated Pesticides/PCB's Sulfate Aldrin Chlordane (Technical) Nutrients Dieldrin Endrin Ammonia Heptachlor Nitrate Heptachlor Epoxide Nitrite Lindane (gamma-BHC) o-Phosphate Metolachlor Total Phosphorus Methoxychlor PCB's (individual aroclors) Note 1 PCB's (as decachlorobiphenyl) Note 1 Demands Toxaphene TOC Nitrogen-Phosphorus Compounds Alachlor Metals Atrazine Aluminum Butachlor Antimony Diquat Arsenic Glyphosate Barium Metribuzin Beryllium Paraquat Boron Propachlor Cadmium Simazine Calcium Chromium Copper SVOC's Iron Benzo(a)pyrene Lead bis-(2-ethylhexyl)phthalate Magnesium bis-(ethylhexyl)adipate Manganese Hexachlorobenzene Mercury Hexachlorocyclopentadiene Molybdenum Nickel Potassium Miscellaneous Organics Selenium Dibromochloropropane (DBCP) Silver Ethylene Dibromide (EDB)
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Lindane Shampoo Reference Number: CP.PMN.09 Effective Date: 11.01.06 Last Review Date: 08.20 Line of Business: Medicaid Revision Log
    Clinical Policy: Lindane Shampoo Reference Number: CP.PMN.09 Effective Date: 11.01.06 Last Review Date: 08.20 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Lindane is an ectoparasiticide and ovicide effective against Pediculus humanus capitis (head lice), Pthirus pubis (crab lice), and their ova. FDA Approved Indication(s) Lindane Shampoo is indicated for the treatment of head lice (infestations of Pediculus humanus capitis), crab lice (infestations of Pthirus pubis), and their ova only in patients who cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. It is the policy of health plans affiliated with Centene Corporation® that Lindane shampoo is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Head Lice (must meet all): 1. Diagnosis of Pediculus capitis (head lice); 2. Failure of two preferred agents indicated for head lice (see Appendix B for examples), at least one of which was used within the past 60 days, unless ALL preferred agents for head lice are contraindicated or clinically significant adverse effects are experienced; 3. Request does not exceed 1 bottle (60 mL) per treatment course. Approval duration: 14 days B. Crab Lice (must meet all): 1. Diagnosis of Phthirus pubis (crab lice); 2. Failure of pyrethrins/piperonyl butoxide AND permethrin 1% cream, used in last 60 days, unless both are contraindicated or clinically significant adverse effects are experienced; 3.
    [Show full text]
  • Pericardial, Retroperitoneal, and Pleural Fibrosis Induced by Pergolide
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.66.1.79 on 1 January 1999. Downloaded from J Neurol Neurosurg Psychiatry 1999;66:79–81 79 SHORT REPORT Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide S Shaunak, A Wilkins, J B Pilling, D J Dick Abstract 1992, the emergence of motor fluctuations led Three patients with Parkinson’s disease to the introduction of pergolide, and the dose are described who developed pericardial, of this was gradually increased to a maximum retroperitoneal, and pleural fibrosis asso- of 1mg/day. 1n 1994, 2 years after the ciated with pergolide treatment. Surgical introduction of pergolide, the patient devel- intervention was required in all three oped left flank pain with weight loss, and was cases, either to reach a tissue diagnosis or found to have a mild anaemia (haemoglobin for potentially life threatening complica- 10.4 g/dl), with indices suggesting iron defi- tions. Symptoms emerged on average 2 ciency, and an ESR of 40 mm/h. Upper gastro- years after the institution of treatment, intestinal endoscopy and barium enema gave and were suYciently non-specific to cause negative results. Seven months later right sided significant delays in diagnosis in all cases. chest pain and a non-productive cough devel- The erythrocyte sedimentation rate (ESR) oped; investigations confirmed persistent anae- was raised in the two patients in whom it mia, an ESR of 55 mm/h, and bilateral pleural was measured. Serosal fibrosis is a rarely thickening on chest radiography and CT. Lung reported adverse eVect of pergolide treat- function tests showed a reduction in total lung ment, although it is well described with capacity of 36% with no fall in transfer factor, other dopamine agonists.
    [Show full text]
  • Lab Standard Operating Procedures (Sops)
    QAPP –Watershed Watch Laboratory Assays Revision: 7 Date: September 2020 Appendix A Standard Operation Procedures List of SOPs SOP SOP Revision Description Number Date General Laboratory Safety 001 11/04 1 URI Laboratory Waste Guidebook 001a 09/13 3 URI laboratory Chemical Hygiene Plan 001b 07/04 Laboratory Water 002 11/16 3 General Labware Cleaning Procedure 003 07/19 4 General Autoclave Operation 004 10/18 6 Bottle Autoclaving Procedure 005 01/16 5 Waste Autoclaving Procedure 006 01/16 3 Chlorophyll-A Analysis, Welschmeyer Method 012 04/18 6 Chloride Analysis 013 11/16 5 Ammonia Analysis 014 11/16 5 Orthophosphate and Nitrate + Nitrite Analysis 015 12/16 5 Total Phosphorus and Nitrogen Analysis 016 12/16 5 Salinity Analysis Using a Refractometer 017 11/16 1 Enterococci Analysis Using Enterolert IDEXX Method 018 12/19 4 Analytical Balance Calibration 019 2/06 2 pH Procedure 021 12/19 3 Alkalinity Procedure 022 11/16 2 Filtering Water Samples 023 10/18 2 Fecal coliform Analysis Using Colilert 18 IDEXX 024 01/16 2 Method Laboratory Thermometer Calibration 025 04/19 1 Heterotrophic Plate Count – Quanti-tray 026 05/20 1 Appendix A Standard Operating Procedure 001 Date: 11/04 General Laboratory Safety Revision: 1 Author: Linda Green University of Rhode Island Watershed Watch 1.0 PURPOSE AND DESCRIPTION LAB SAFETY IS EVERYBODY’S JOB! Please be sure to familiarize yourself with these general procedures, as well as the specific handling requirements included in the Standard Operating Procedure (SOP) for each analysis/process. Further general information regarding University of Rhode Island standards for health and safety are found in SOP 001a – University Safety and Waste Handling Document.
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Evidence from Horses with Pituitary Pars Intermedia Dysfunction Jessica S
    Fortin et al. BMC Veterinary Research (2020) 16:356 https://doi.org/10.1186/s12917-020-02565-3 RESEARCH ARTICLE Open Access Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction Jessica S. Fortin1*, Matthew J. Benskey2, Keith J. Lookingland2, Jon S. Patterson1, Erin B. Howey1, John L. Goudreau2,3 and Harold C. Schott II4* Abstract Background: Pituitary pars intermedia dysfunction (PPID) develops slowly in aged horses as degeneration of hypothalamic dopaminergic neurons leads to proliferation of pars intermedia (PI) melanotropes through hyperplasia and adenoma formation. Dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity are markedly reduced in PI tissue of PPID-affected equids and treatment with the DA receptor agonist pergolide results in notable clinical improvement. Thus, we hypothesized that pergolide treatment of PPID-affected horses would result in greater DA and TH levels in PI tissue collected from PPID-affected horses versus untreated PPID-affected horses. To test this hypothesis, pituitary glands were removed from 18 horses: four untreated PPID-affected horses, four aged and four young horses without signs of PPID, and six PPID-affected horses that had been treated with pergolide at 2 µg/kg orally once daily for 6 months. DA concentrations and TH expression levels in PI tissues were determined by high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively. Results: DA and TH levels were lowest in PI collected from untreated PPID-affected horses while levels in the pergolide treated horses were similar to those of aged horses without signs of PPID.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Design, Synthesis, and Evaluation of Antiepileptic Compounds Based on Β-Alanine and Isatin
    Design, Synthesis, and Evaluation of Antiepileptic Compounds Based on β-Alanine and Isatin by Robert Philip Colaguori A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Pharmaceutical Sciences University of Toronto © Copyright by Robert Philip Colaguori, 2016 ii Design, Synthesis, and Evaluation of Antiepileptic Compounds Based on β-Alanine and Isatin Robert Philip Colaguori Master of Science Department of Pharmaceutical Sciences University of Toronto 2016 Abstract Epilepsy is the fourth-most common neurological disorder in the world. Approximately 70% of cases can be controlled with therapeutics, however 30% remain pharmacoresistant. There is no cure for the disorder, and patients affected are subsequently medicated for life. Thus, there is a need to develop compounds that can treat not only the symptoms, but also delay/prevent progression. Previous work resulted in the discovery of NC-2505, a substituted β-alanine with activity against chemically induced seizures. Several N- and α-substituted derivatives of this compound were synthesized and evaluated in the kindling model and 4-AP model of epilepsy. In the kindling model, RC1-080 and RC1-102 were able to decrease the mean seizure score from 5 to 3 in aged mice. RC1-085 decreased the interevent interval by a factor of 2 in the 4-AP model. Future studies are focused on the synthesis of further compounds to gain insight on structure necessary for activity. iii Acknowledgments First and foremost, I would like to thank my supervisor Dr. Donald Weaver for allowing me to join the lab as a graduate student and perform the work ultimately resulting in this thesis.
    [Show full text]